Paratek Pharmaceuticals, Inc.
PRTK
PRTK was delisted on the 20th of September, 2023.
76 hedge funds and large institutions have $42.6M invested in Paratek Pharmaceuticals, Inc. in 2022 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 19 increasing their positions, 29 reducing their positions, and 8 closing their positions.
535% more call options, than puts
Call options by funds: $108K | Put options by funds: $17K
63% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 8
6% more funds holding
Funds holding: 72 → 76 (+4)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
29% less capital invested
Capital invested by funds: $59.8M → $42.6M (-$17.3M)
34% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$684K |
| 2 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$672K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$562K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$402K |
| 5 |
TI
Telemetry Investments
New York
|
+$344K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
1CM
1492 Capital Management
Milwaukee,
Wisconsin
|
-$1.29M |
| 2 |
JGC
J. Goldman & Co
New York
|
-$1.02M |
| 3 |
Two Sigma Investments
New York
|
-$708K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
-$605K |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$207K |
PRTK Hedge Fund Activity: Q4 2022 in Review
76 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Paratek Pharmaceuticals, Inc. (PRTK) for Q4 2022, worth a combined $42.6M — down 29% from $59.8M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new PRTK positions and 8 closed out — a net gain of 5 holders — while 19 added to existing stakes and 29 trimmed.
The largest buyer was Millennium Management, adding an estimated $684K. The largest seller was 1492 Capital Management, exiting entirely with an estimated $1.29M sold.
- 76 institutional investors held Paratek Pharmaceuticals, Inc. (PRTK) as of Q4 2022, up from 72 in Q3 2022.
- Funds reported $42.6M of Paratek Pharmaceuticals, Inc. stock for Q4 2022, down 29% quarter-over-quarter.
- 13 funds opened new Paratek Pharmaceuticals, Inc. positions in Q4 2022 and 8 closed out, a net change of +5 holders.
- The largest Paratek Pharmaceuticals, Inc. buyer in Q4 2022 was Millennium Management, an estimated $684K added.
- The largest Paratek Pharmaceuticals, Inc. seller in Q4 2022 was 1492 Capital Management, an estimated $1.29M sold.
Based on aggregated 13F filings for Q4 2022.